FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					_		()				1 /			_					
1. Name and Address of Reporting Person* Ber Gerard						2. Issuer Name and Ticker or Trading Symbol Lantheus Holdings, Inc. [LNTH]								(Che	ck all applic	cable) or	g Person(s) to Is: 10% O		
	NTHEUS H	OLDINGS, INC	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/19/2020									Officer below)	(give title	title Other (s below)		specify
331 TREBLE COVE ROAD (Street) NORTH BILLERICA MA 01862				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. In Line	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date				2. Trans Date (Month)		ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Transaction Disposed Code (Instr. 5)		ities Acquired (A) o d Of (D) (Instr. 3, 4			5. Amou Securitie Benefici Owned F Reporter	es ally Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership
				Code	v	Amount	mount (A) or P		Price	Transact	tion(s)			(Instr. 4)					
Common Stock 06/1					9/202	9/2020		A		5,98	,981 A S		\$0.00	5,	5,981		D		
Common Stock 06/15				9/202	9/2020		A		15,50	15,500 A		(1)	21,481			D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day	Date,	4. Transaction Code (Instr. 3)		of		6. Date Exercisable Expiration Date (Month/Day/Year)		!	le and 7. Title and Ai of Securities Underlying Derivative Se (Instr. 3 and 4		curity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	Owners Form: Direct or Indii (I) (Inst	Ownership	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	or Nu of	umber					
Non- Qualified Stock Option (Right to Buy)	\$16.17	06/19/2020			A		17,481		06/19/202	0 1	2/13/2029	Commo stock	n 1	7,481	(2)	17,48	1	D	

Explanation of Responses:

1. Received in exchange for 50,000 shares of Progenics Pharmaceuticals, Inc. ("Progenics"), in connection with the merger of Progenics pursuant to the Amended and Restated Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 20, 2020, by and among Lantheus Holdings, Inc. (the "Company"), Plato Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub"), and Progenics, pursuant to which Merger Sub merged with and into Progenics, with Progenics surviving as a wholly owned subsidiary of the Company (the "Merger").

Remarks:

/s/ Daniel Niedzwiecki, 06/23/2020 attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} Received in the Merger in exchange for a non-qualified stock option to acquire 56,393 shares of Progenics for \$5.01 per share.